Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of CVL237 in PTEN-deficient advanced solid tumors
CTR20240229Phase 2Active
- Sponsor
- Convalife Pharmaceutical
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CVL237 in Nonhematologic neoplasms, gastric cancer (GC), prostate cancer (PCa), endometrial cancer (EC), colorectal cancer (CRC), sponsored by Convalife Pharmaceutical. Started Mar 2024; status: active.
02
Drugs
CVL237
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)prostate cancer (PCa)endometrial cancer (EC)colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20240229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240229.